About Killer cell immunoglobulin-like receptor 3DS1
Killer cell immunoglobulin-like receptor 3DS1 (KIR3DS1) is a protein
from Homo sapiens identified by UniProt accession
Q14943, 382 residues long.
MolForge cross-references it against 0 known binders and
73 disease associations.
Target properties
| Protein name | Killer cell immunoglobulin-like receptor 3DS1 |
|---|
| UniProt accession | Q14943 |
|---|
| Gene | KIR3DS1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 382 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (73)
Diseases linked to this target (Open Targets).
- psoriasis · score 0.04
- ocular toxoplasmosis · score 0.04
- chronic hepatitis B virus infection · score 0.04
- Hodgkins lymphoma · score 0.04
- infect · score 0.03
- infection · score 0.03
- hepatitis B virus infection · score 0.02
- HIV-1 infection · score 0.02
- acute myeloid leukemia · score 0.02
- HIV infection · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q14943-F1 | alphafold | PREDICTED | 80.81 | — |
Amino-acid sequence (382 residues)
MLLMVVSMAC VGLFLVQRAG PHMGGQDKPF LSAWPSAVVP RGGHVTLRCH YRHRFNNFML YKEDRIHVPI FHGRIFQEGF NMSPVTTAHA GNYTCRGSHP HSPTGWSAPS NPMVIMVTGN HRKPSLLAHP GPLVKSGERV ILQCWSDIMF EHFFLHREWI SKDPSRLVGQ IHDGVSKANF SIGSMMRALA GTYRCYGSVT HTPYQLSAPS DPLDIVVTGL YEKPSLSAQP GPKVQAGESV TLSCSSRSSY DMYHLSREGG AHERRLPAVR KVNRTFQADF PLGPATHGGT YRCFGSFRHS PYEWSDPSDP LLVSVTGNPS SSWPSPTEPS SKSGNLRHLH ILIGTSVVKI PFTILLFFLL HRWCSNKKKC CCNGPRACRE QK
Explore Killer cell immunoglobulin-like receptor 3DS1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets